For GA, secondary to AMD

NAVIGATING PAYER COVERAGE

See how SYFOVRE️
is covered
Woman smiling at the camera

Coverage policies are subject to change and vary from plan to plan.

Refer to the SYFOVRE coverage lookup tool for coverage policies by plan

This tool should not be considered a guarantee of coverage or reimbursement, and you should 
always consult your patient’s insurer for the latest coverage details.

LOOK UP PAYER POLICIESGo to external site
Blue award ribbon

100% SYFOVRE payer coverage for Traditional Medicare and robust coverage for Medicare Advantage and Commercial lives in the United States1,a

aData as of January 2025.

Navigating the prior authorization (PA) process

Some health plans may require a PA describing your patient’s medical history and the reasons why you feel SYFOVRE is the right medication for your patient. Other plans may require a precertification for the CPT code based on site of care. It is important to check with your patient’s health plan to ensure you are using the correct form and supplying all of the required information. To avoid delays, it is recommended to consider including a Letter of Medical Necessity to support the PA submission.

Refer to the checklist and resources below for guidance on fulfilling PA requirements. Or contact your Apellis Field Reimbursement Manager (FRM) or call ApellisAssist at 888-APELLIS (888-273-5547) for information on PA requirements.

PA checklist

Helpful reminders for the PA process

  • Confirm PA requirements and how the PA should be submitted (eg, fax, phone, or online)
  • Determine if the health plan has a specific form that must be used and if it is available online
  • Check the health plan’s policy for treatment with SYFOVRE to ensure medical documentation addresses specific policy requirements
  • Use the appropriate billing codes

Refer to the Access & Reimbursement Guide

for more information

DOWNLOADDownload resource

Letter of Medical Necessity

(some payers may require this)

  • Be specific in your request (ie, requesting approval of the PA to support the prescribed medication)
  • Highlight the clinical assessments that demonstrate the patient need and that the patient meets the health plan medical policy criteria for treatment with SYFOVRE
  • Include a copy of the health plan medical policy, if available
  • Include your office’s contact information


Refer to the Sample Letter of Medical Necessity
for examples of the types of information you may want to include

DOWNLOADDownload resource

What happens next?

  1. If the PA is approved, be sure to document the PA approval number/date in the patient’s record and make note of the expiration date
  2. If the PA is denied, you can file an appeal. The ApellisAssist program can provide information about how to submit the appeal. The following PA denial appeal checklist may be helpful as you’re preparing an appeal:
  • Review the denial letter to understand the reason for the denial and note any deadlines for next steps
  • Compile supporting medical information, documentation, and clinical assessments
  • Submit the first appeal per the health plan’s process and requirements
  • If rejected, submit a second appeal that responds to the health plan’s concerns, questions, or requirements
  • Many health plans’ appeal policies allow up to 2 levels of internal appeal for PA denials. You may have the right to request an external appeal, which can include a review by an independent expert not affiliated with the health plan or an external review board. Be sure to note any deadlines for these additional appeals

Refer to the Sample Letter of Appeals for examples of the types of information you may want to include

DOWNLOADDownload resource

Help your eligible patients save on their out-of-pocket costs for SYFOVRE.

AMD=age-related macular degeneration; GA=geographic atrophy.
Reference: 1. Data on file. Apellis Pharmaceuticals, Inc; 2024.

Back to top of page button Back to top of page button

IMPORTANT SAFETY INFORMATION 

INDICATION

CONTRAINDICATIONS

  • SYFOVRE is contraindicated in patients with ocular or periocular infections, in patients with active intraocular inflammation, and in patients with hypersensitivity to pegcetacoplan or any of the excipients in SYFOVRE. Systemic hypersensitivity reactions (e.g., anaphylaxis, rash, urticaria) have occurred.

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

WARNINGS AND PRECAUTIONS

  • Endophthalmitis and Retinal Detachments

    • Intravitreal injections, including those with SYFOVRE, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering SYFOVRE to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Retinal Vasculitis and/or Retinal Vascular Occlusion

    • Retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, have been reported with the use of SYFOVRE. Cases may occur with the first dose of SYFOVRE and may result in severe vision loss. Discontinue treatment with SYFOVRE in patients who develop these events. Patients should be instructed to report any change in vision without delay.
  • Neovascular AMD

    • In clinical trials, use of SYFOVRE was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (12% when administered monthly, 7% when administered every other month and 3% in the control group) by Month 24. Patients receiving SYFOVRE should be monitored for signs of neovascular AMD. In case anti-Vascular Endothelial Growth Factor (anti-VEGF) is required, it should be given separately from SYFOVRE administration.
  • Intraocular Inflammation

    • In clinical trials, use of SYFOVRE was associated with episodes of intraocular inflammation including: vitritis, vitreal cells, iridocyclitis, uveitis, anterior chamber cells, iritis, and anterior chamber flare. After inflammation resolves, patients may resume treatment with SYFOVRE.
  • Increased Intraocular Pressure

    • Acute increase in IOP may occur within minutes of any intravitreal injection, including with SYFOVRE. Perfusion of the optic nerve head should be monitored following the injection and managed as needed.

ADVERSE REACTIONS

  • Most common adverse reactions (incidence ≥5%) are ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, conjunctival hemorrhage.

INDICATION

SYFOVRE® (pegcetacoplan injection) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Please see full Prescribing Information for more information